Mesoblast Limited (MESO)
(Delayed Data from NSDQ)
$7.23 USD
+0.13 (1.83%)
Updated Jul 19, 2024 04:00 PM ET
After-Market: $7.20 -0.03 (-0.41%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth A Momentum F VGM
Price, Consensus and EPS Surprise
MESO 7.23 +0.13(1.83%)
Will MESO be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for MESO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MESO
Mesoblast (MESO) Soars 208% YTD on Positive Regulatory Updates
Mesoblast (MESO) to File Pediatric GVHD Drug BLA, Stock Up
MESO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Mesoblast (MESO) Up on Rare Pediatric Disease Tag for Heart Drug
Mesoblast Limited (MESO) Loses -5.45% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
5 Stocks to Ride the Santa Claus Rally
Other News for MESO
Mesoblast: Rolling The Dice On Cellular Medicines
Patient Enrollment Commenced in Pivotal Phase 3 Trial of Rexlemestrocel-L for Chronic Low Back Pain
Mesoblast Limited (MEOBF) was downgraded to a Hold Rating at Jefferies
Mesoblast Resubmits Biologics License Application (BLA) with United States Food & Drug Administration (FDA) for Approval of Ryoncil® in Children with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)
Mesoblast Eyes FDA Approval and Extends Patent Portfolio